Sources and updates, May 28
Sources and updates for the week of May 28 include new Long COVID papers, FDA approval for Paxlovid, bivalent vaccine protection, and more.
Read MoreSources and updates for the week of May 28 include new Long COVID papers, FDA approval for Paxlovid, bivalent vaccine protection, and more.
Read MoreSources and updates for the week of May 21 include new funding from the CDC’s forecasting center, keeping masks in healthcare, drug overdoses, and more.
Read MoreSources and updates for the week of May 7 include tracking Medicaid coverage, vaccine mandates, disparities in COVID-19 deaths, and more.
Read MoreSources and updates for the week of April 23 include a people’s review of the CDC, COVIDTests.gov usage, vaccine equity, and more.
Read MoreThis week, the FDA made some adjustments to the U.S.’s COVID-19 vaccine guidance in order to standardize all new mRNA shots to bivalent (or Omicron-specific) vaccines, and to allow adults at higher risk to receive additional boosters. The CDC’s vaccine advisory committee and Director Rochelle Walensky both endorsed these changes.
Read MoreThis week, the White House announced that it’s setting up a $5 billion program, called Project Next Gen, to support next-generation COVID-19 vaccines and treatments. Project Next Gen is a big step toward actually ending the pandemic, not just pretending it’s over. The federal government can support large-scale clinical trials and speed up regulatory approval in a way that no research group or company could. Still, the U.S.’s prior vaccine campaigns don’t inspire confidence that this project will lead to widespread adoption of new shots when they become available.
Read MoreSources and updates for the week of February 26 include deaths in U.S. prisons, the future of COVID-19 vaccines, airplane wastewater testing, and more.
Read MoreSources and updates for the week of February 12 include routine vaccinations for kids, variant analysis in China, ME/CFS research, and more.
Read MoreSources and updates for the week of February 5 include modeling persistent COVID-19 risk, global vaccination coverage, COVID-related lawsuits, and more.
Read MoreOn Thursday, the FDA’s Vaccines and Related Biological Products Advisory Committee (or VRBPAC) met to discuss the future of COVID-19 vaccines. While the committee readily agreed that our current, Omicron-specific shots are working well and should be used more broadly, it had a hard time answering other questions about future vaccine regimens—largely due to a lack of good data.
Read More